Cargando…
Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients
COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), is estimated to have caused over 6.5 million deaths worldwide. The emergence of fast-evolving SARS-CoV-2 variants of concern alongside increased transmissibility and/or virulence, as well as immune and vaccine esca...
Autores principales: | Giotis, Efstathios S., Cil, Emine, Brooke, Greg N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788624/ https://www.ncbi.nlm.nih.gov/pubmed/36560732 http://dx.doi.org/10.3390/v14122728 |
Ejemplares similares
-
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
por: Leach, D. A., et al.
Publicado: (2021) -
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021) -
Antiandrogens Target TMPRSS2 and Reduce SARS-CoV-2 Virus Entry in Lung Cells
por: Leach, Damien A, et al.
Publicado: (2021) -
Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells
por: Brooke, Greg N., et al.
Publicado: (2015) -
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)